Product Information

What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide belonging to the melanocortin receptor agonist class. Unlike compounds that act primarily through vascular mechanisms, PT-141 has been investigated for its interaction with melanocortin receptors located within the central nervous system.

Its unique mechanism of action has made PT-141 one of the most widely recognised and extensively discussed peptides within its category, generating continued scientific interest across numerous published studies.

Mechanism of Action

PT-141 selectively activates melanocortin receptors, particularly MC3R and MC4R, within the central nervous system.

Rather than acting directly on blood vessels or smooth muscle tissue, PT-141 influences neurological signalling pathways involved in melanocortin receptor activity.

This distinct pharmacological profile differentiates PT-141 from many other compounds investigated within similar areas of scientific interest.

Product Specifications

Available Strength

10mg.

Compound Type

Synthetic melanocortin receptor agonist peptide.

Independent Verification

Every batch is independently Janoshik Verified for confirmed identity and purity.

Batch Documentation

Verification reports are issued specifically for Baseline Labs, making us the only seller in the Philippines to provide Janoshik reports issued under our own name rather than relying on generic manufacturer documentation.

Independent Quality Verification

Every batch of PT-141 supplied by Baseline Labs is independently verified by Janoshik Analytical.

Unlike generic manufacturer Certificates of Analysis that may accompany products from multiple suppliers, our verification report is issued specifically for Baseline Labs, providing documented third-party confirmation of the product's identity and purity.

This additional level of transparency helps demonstrate our commitment to quality, consistency and independent verification.

Storage Recommendations

For maximum stability, unopened vials should be stored refrigerated between 2°C and 8°C.

For extended storage, unopened vials may also be frozen provided they are protected from repeated freeze-thaw cycles.

After reconstitution, refrigeration is recommended. Avoid prolonged exposure to heat, direct sunlight and repeated temperature fluctuations.

Reconstitution

PT-141 is commonly reconstituted using bacteriostatic water under clean handling conditions.

Introduce the diluent slowly against the inside wall of the vial before gently swirling until the lyophilised powder has completely dissolved.

Avoid vigorous shaking, as excessive agitation may affect delicate peptide structures.

Packaging

Every order is securely packaged to help protect the product during transit.

Each verified batch includes product identification together with access to the independent Janoshik verification report issued specifically for Baseline Labs.

Why Independent Verification Matters

Independent laboratory verification provides documented confirmation that the tested material matches its stated identity and purity.

Rather than relying solely on manufacturer documentation, Baseline Labs provides independent third-party verification from Janoshik Analytical, giving customers access to a report issued specifically for Baseline Labs.

For a comprehensive review of the published literature, pharmacology and available clinical evidence relating to PT-141, please continue to the Research & Clinical Data section.

Research & Clinical Data

Clinical Development

PT-141, also known as Bremelanotide, has been the subject of extensive scientific investigation due to its unique mechanism of action within the melanocortin system.

Unlike compounds that act primarily through vascular pathways, PT-141 has been studied for its ability to activate melanocortin receptors located within the central nervous system. This distinctive pharmacology has made it one of the most widely recognised peptides in its class.

Melanocortin Receptors

PT-141 primarily interacts with melanocortin receptors, particularly MC3R and MC4R.

These receptors are distributed throughout the central nervous system and are involved in numerous physiological signalling pathways. Their broad distribution has resulted in continued scientific interest regarding the role of melanocortin receptor activation across multiple fields of study.

Mechanism of Action

The pharmacological activity of PT-141 differs significantly from compounds that rely on direct vascular effects.

Instead, PT-141 acts through central melanocortin receptor activation, producing downstream neurological signalling responses that continue to be investigated in published scientific literature.

This unique mechanism remains one of the defining characteristics of the peptide.

Pharmacology

PT-141 was developed as a synthetic melanocortin receptor agonist with high receptor selectivity.

Its receptor binding characteristics, predictable pharmacological profile and well-documented biological activity have contributed to its extensive investigation within both preclinical and clinical settings.

Published Literature

PT-141 has been investigated across numerous areas of scientific interest, including:

Melanocortin receptor signalling

Understanding receptor activation and downstream physiological pathways.

Central nervous system activity

Investigating neurological mechanisms associated with melanocortin receptor stimulation.

Endocrine physiology

Examining interactions between melanocortin signalling and broader endocrine function.

Receptor pharmacology

Studying receptor selectivity, affinity and biological response.

These published investigations continue to expand the understanding of PT-141 and its unique pharmacological properties.

Clinical Investigation

Over the past two decades, PT-141 has been evaluated in multiple clinical and experimental settings.

Its distinct mechanism of action has contributed to a substantial body of published literature examining receptor biology, pharmacokinetics, safety evaluation and physiological activity.

This growing evidence base has established PT-141 as one of the best characterised compounds within the melanocortin receptor agonist category.

Scientific Interest

PT-141 continues to generate scientific interest because its mechanism differs substantially from many other compounds investigated within similar therapeutic areas.

Its receptor specificity and central mechanism of action have made it an important subject of ongoing research into melanocortin receptor biology and associated physiological pathways.

As additional publications become available, understanding of PT-141's pharmacology continues to evolve.

Independent Verification

Every batch of PT-141 supplied by Baseline Labs is independently Janoshik Verified, providing documented confirmation of the product's identity and purity.

Unlike generic manufacturer Certificates of Analysis, our verification report is issued specifically for Baseline Labs. We are the only seller in the Philippines to provide Janoshik reports issued under our own name, giving customers direct access to independent third-party laboratory verification.

For additional information regarding product specifications, storage recommendations and shipping information, please refer to the accompanying sections on this page.